Changing face of medication-related osteonecrosis of the jaw: Sheba Medical Center experience-fifteen years

Sara Whitefield, Towi Sorel Lazarovici, Marina Sommer-Umansky, Silvina Friedlander-Barenboim, Ran Yahalom, Noam Yarom*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Our aim is to track the development of the epidemiological characteristics in patient populations diagnosed with MRONJ at the Sheba Medical Center. Materials and methods: The files of patients diagnosed with MRONJ from 2003 until December 2017 were retrieved. Data on demographics, medical background, type and duration of drug use and triggering events at presentation was collected. Results: The study included 448 patients, 336 females and 112 males. A decrease in the proportion of multiple myeloma patients (p < 0.05) and an increase in the proportion of patients with bone metastases of solid tumors has been observed recently. An increase in the proportion of cases in osteoporosis patients compared with oncology patients is evident (p < 0.01). Overtime a higher proportion of patients presented at an earlier stage of MRONJ (p < 0.01). Conclusions: As a result of changes in treatment protocols and increased awareness of oncology caregivers, including referral and consultation with Oral Medicine specialists, there has been a change in the demographics and presentation of the disease.

Original languageEnglish
Pages (from-to)819-825
Number of pages7
JournalJournal of Bone and Mineral Metabolism
Volume38
Issue number6
DOIs
StatePublished - 1 Nov 2020

Keywords

  • Bone modifying agents
  • Jaws
  • MRONJ
  • Osteonecrosis

Fingerprint

Dive into the research topics of 'Changing face of medication-related osteonecrosis of the jaw: Sheba Medical Center experience-fifteen years'. Together they form a unique fingerprint.

Cite this